Cargando…

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation

Background: The recently developed antiandrogen, Enzalutamide (Enz), has reformed the standard of care for castration resistant prostate cancer (CRPC) patients. However, Enz-resistance inevitably emerges despite success of Enz in prolonging CRPC patients’ survival. Here we found that Enz-resistant p...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hua, Sun, Yin, Huang, Chi-Ping, You, Bosen, Ye, Dingwei, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226306/
https://www.ncbi.nlm.nih.gov/pubmed/32235588
http://dx.doi.org/10.3390/cancers12040831
_version_ 1783534258105614336
author Xu, Hua
Sun, Yin
Huang, Chi-Ping
You, Bosen
Ye, Dingwei
Chang, Chawnshang
author_facet Xu, Hua
Sun, Yin
Huang, Chi-Ping
You, Bosen
Ye, Dingwei
Chang, Chawnshang
author_sort Xu, Hua
collection PubMed
description Background: The recently developed antiandrogen, Enzalutamide (Enz), has reformed the standard of care for castration resistant prostate cancer (CRPC) patients. However, Enz-resistance inevitably emerges despite success of Enz in prolonging CRPC patients’ survival. Here we found that Enz-resistant prostate cancer (PCa) cells had higher BCL2 expression. We aimed to test whether targeting BCL2 would influence Enz sensitivity of prostate cancer (PCa) and identify the potential mechanism. Methods: The study was designed to target Enz-induced BCL2 with inhibitor ABT263 and test Enz sensitivity in Enz-resistant PCa cells by MTT assay. Cellular reactive oxygen species (ROS) levels were detected with dihydroethidium staining, and in vitro deubiquitinating enzyme activity assay was used to evaluate ubiquitin specific protease 26 (USP26) activity. Results: ABT263 could increase Enz sensitivity in both Enz-sensitive and Enz-resistant PCa cells via inducing ROS generation. Elevated cellular ROS levels might then inhibit USP26 activity to increase the ubiquitination of androgen receptor (AR) and AR splice variant 7 (ARv7) and their ubiquitin/proteasome-dependent degradation, which contributed to the increase of Enz sensitivity. In vivo mouse model also demonstrates that ABT263 will suppress the PCa progression. Conclusion: This study demonstrated that targeting Enz-induced BCL2 with inhibitor ABT263 could increase Enz sensitivity in both Enz-sensitive and Enz-resistant PCa cells through induction of cellular ROS levels and suppression of USP26 activity with a consequent increase of ubiquitin/proteasome-dependent degradation of AR and ARv7 protein expression.
format Online
Article
Text
id pubmed-7226306
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72263062020-05-18 Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation Xu, Hua Sun, Yin Huang, Chi-Ping You, Bosen Ye, Dingwei Chang, Chawnshang Cancers (Basel) Article Background: The recently developed antiandrogen, Enzalutamide (Enz), has reformed the standard of care for castration resistant prostate cancer (CRPC) patients. However, Enz-resistance inevitably emerges despite success of Enz in prolonging CRPC patients’ survival. Here we found that Enz-resistant prostate cancer (PCa) cells had higher BCL2 expression. We aimed to test whether targeting BCL2 would influence Enz sensitivity of prostate cancer (PCa) and identify the potential mechanism. Methods: The study was designed to target Enz-induced BCL2 with inhibitor ABT263 and test Enz sensitivity in Enz-resistant PCa cells by MTT assay. Cellular reactive oxygen species (ROS) levels were detected with dihydroethidium staining, and in vitro deubiquitinating enzyme activity assay was used to evaluate ubiquitin specific protease 26 (USP26) activity. Results: ABT263 could increase Enz sensitivity in both Enz-sensitive and Enz-resistant PCa cells via inducing ROS generation. Elevated cellular ROS levels might then inhibit USP26 activity to increase the ubiquitination of androgen receptor (AR) and AR splice variant 7 (ARv7) and their ubiquitin/proteasome-dependent degradation, which contributed to the increase of Enz sensitivity. In vivo mouse model also demonstrates that ABT263 will suppress the PCa progression. Conclusion: This study demonstrated that targeting Enz-induced BCL2 with inhibitor ABT263 could increase Enz sensitivity in both Enz-sensitive and Enz-resistant PCa cells through induction of cellular ROS levels and suppression of USP26 activity with a consequent increase of ubiquitin/proteasome-dependent degradation of AR and ARv7 protein expression. MDPI 2020-03-30 /pmc/articles/PMC7226306/ /pubmed/32235588 http://dx.doi.org/10.3390/cancers12040831 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xu, Hua
Sun, Yin
Huang, Chi-Ping
You, Bosen
Ye, Dingwei
Chang, Chawnshang
Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
title Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
title_full Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
title_fullStr Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
title_full_unstemmed Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
title_short Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
title_sort preclinical study using abt263 to increase enzalutamide sensitivity to suppress prostate cancer progression via targeting bcl2/ros/usp26 axis through altering arv7 protein degradation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226306/
https://www.ncbi.nlm.nih.gov/pubmed/32235588
http://dx.doi.org/10.3390/cancers12040831
work_keys_str_mv AT xuhua preclinicalstudyusingabt263toincreaseenzalutamidesensitivitytosuppressprostatecancerprogressionviatargetingbcl2rosusp26axisthroughalteringarv7proteindegradation
AT sunyin preclinicalstudyusingabt263toincreaseenzalutamidesensitivitytosuppressprostatecancerprogressionviatargetingbcl2rosusp26axisthroughalteringarv7proteindegradation
AT huangchiping preclinicalstudyusingabt263toincreaseenzalutamidesensitivitytosuppressprostatecancerprogressionviatargetingbcl2rosusp26axisthroughalteringarv7proteindegradation
AT youbosen preclinicalstudyusingabt263toincreaseenzalutamidesensitivitytosuppressprostatecancerprogressionviatargetingbcl2rosusp26axisthroughalteringarv7proteindegradation
AT yedingwei preclinicalstudyusingabt263toincreaseenzalutamidesensitivitytosuppressprostatecancerprogressionviatargetingbcl2rosusp26axisthroughalteringarv7proteindegradation
AT changchawnshang preclinicalstudyusingabt263toincreaseenzalutamidesensitivitytosuppressprostatecancerprogressionviatargetingbcl2rosusp26axisthroughalteringarv7proteindegradation